Dr Reddy Laboratories Launches Generic Singulair - Quick Facts

Dr. Reddy's Laboratories Settles Its Claims Against Nordion

Trade RDY now with

8/7/2012 8:55 AM ET

Dr Reddy Laboratories Ltd (RDY: Quote) Tuesday said it has launched Montelukast Sodium Tablets 10 mg and Montelukast Sodium Chewable Tablets of 4 mg and 5 mg in the US market on August 6, after the United States Food & Drug Administration approved its ANDA.

These are bioequivalent generic versions of Singulair tablets and chewable tablets. Dr. Reddy's said its Montelukast Sodium Tablets in 10 mg and Montelukast Sodium Chewable Tablets in 4 mg and 5 mg are available in bottle counts of 30 and 90.

The Singulair tablets and Chewable tablets brand had U.S. sales of around $3.6 billion and $1.14 billion, respectively, for the twelve months ending March 2012, according to IMS Health.

Click here to receive FREE breaking news email alerts for Dr Reddy Laboratories Ltd and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 128 Articles Next>>

Editors Pick

HP Profit Falls Yet Tops Estimates

Hewlett-Packard Co. said Wednesday after the markets closed that its second quarter profit fell 32% from last year, hurt by lower revenue and weaker margins amid a slump in PC sales. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.

Worries About Fed Tapering Lead To Sell-Off On Wall Street - U.S. Commentary

Stocks showed a substantial downturn over the course of the trading day on Wednesday after seeing some strength in morning trading. Renewed worries about the Federal Reserve tapering its asset purchase program contributed to the sharp pullback by the markets. The major averages climbed off their worst levels going into the close but still ended the day firmly negative.

Fed Minutes Show Some Members Want To Scale Back QE3 This Summer

Some members of the Federal Reserve favor scaling back the central bank's $85 billion a month asset purchase program this summer as long as the economy continues to improve, according the the minutes of the Fed's April 30-May 1 meeting. "A number of participants expressed willingness to adjust the...